Developer docs
API playgroundTry for free, no card

Search company profiles

JeNaCell

Full company profile

uuid000eccf

Namestring
JeNaCell
Legal namestring
JeNaCell GmbH
Websiteurl
jenacell.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

JeNaCell GmbH is a German specialty biomaterials company that develops and manufactures biosynthetic cellulose products for medical device, pharmaceutical, and professional skin care applications. Founded in 2012 as a spin-off from Friedrich Schiller University of Jena and acquired by Evonik Industries AG in 2021, the company operates today as a wholly-owned subsidiary within Evonik's Health Care division, with its headquarters and production facilities in Jena, Germany.

The company's core technology is a proprietary biotechnological fermentation process that uses a protected acetic acid bacteria strain to produce biosynthetic cellulose — a nature-inspired hydropolymer consisting of approximately 5% cellulose and 95% water with a 3D nanofiber network. Manufacturing is conducted at commercial scale using a globally unique, automated technology enabling continuous planar production, and the production process is certified to DIN EN ISO 13485:2016. JeNaCell's product portfolio centers on two brands: the biocellic® base material, offered for custom development partnerships in drug delivery, transdermal patches, and dermatological formulations, and the epicite® wound dressing line, with three variants — epicite® BALANCE for chronic wounds, epicite® CALM for post-aesthetic treatment care, and epicite® RESCUE for advanced burn treatment.

The business operates an enterprise field-sales go-to-market, engaging medical device, pharmaceutical, and cosmetic customers through direct contact, trade show participation, and scientific congress presence across Europe and globally. Revenue is generated through three primary streams: branded epicite® product sales, custom development services leveraging JeNaCell's process and product design expertise, and licensing of biocellic® base material to industrial partners. Pricing is not publicly disclosed and is handled via direct inquiry. The company maintains a small team (1-10 employees) and provides no public revenue figures.

Short descriptiontext

JeNaCell GmbH is a German biosynthetic cellulose manufacturer producing epicite® wound dressings and biocellic® base materials for medical device, pharmaceutical, and cosmetic industry partners. A wholly-owned Evonik Industries subsidiary founded in 2012.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersJena, Germany
HQ citystring
Jena
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosynthetic cellulose, wound care dressings, biotech biomaterials, drug delivery systems, medical device materials
Industry4 codes
PRIMARYIMAMALAD
Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters)
SECONDARYIMAMALAB
Biochemicals & Bio-based Platform Chemicals (cellulose sugars, lignin derivatives, organic acids)
SECONDARYIMAMALAL
Biorefinery Technology & Contract Processing (fractionation, tolling, scale-up)
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Artificial and Synthetic Fibers and Filaments Manufacturing32522
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Plastic Material, Synth Resin/Rubber, Cellulos (No Glass)2820
  • Surgical & Medical Instruments & Apparatus3841
Product category
Biomedical Materials
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales (epicite® Brand)
TypeOne Time License
Description

Sale of branded wound dressing products including epicite® BALANCE for chronic wounds, epicite® CALM for medical aesthetics post-treatment care, and epicite® RESCUE for advanced burn treatment. Products are medical device quality hydro-active dressings.

jenacell.com
2Custom Development Services
TypeProfessional Services
Description

Partnering with customers to develop customized biosynthetic cellulose solutions for drug delivery, medical devices, and cosmetic applications. Customers benefit from JeNaCell's expertise in process and product design, biosynthetic cellulose technology, and academic/industrial partner network.

jenacell.com
3biocellic® Material Licensing
TypeLicensing Royalties
Description

Licensing of biosynthetic cellulose base material biocellic® to pharmaceutical and cosmetic companies for custom developments in drug delivery systems, transdermal patches, and dermatological applications.

jenacell.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1epicite® BALANCE
Description

Wound dressings designed for the treatment of chronic and slow healing wounds, composed of biosynthetic cellulose and more than 95 percent isotonic saline.

jenacell.com
+3 more records
Core offering1 text field

JeNaCell develops and manufactures biosynthetic cellulose-based products using a proprietary biotechnological fermentation process with acetic acid bacteria. The portfolio centers on the biocellic® base material and the epicite® wound dressing brand (BALANCE for chronic wounds, CALM for post-aesthetic treatment care, RESCUE for advanced burn treatment), supported by custom biomaterial development services for medical device, pharmaceutical, and cosmetic industry partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • No cytotoxic or sensitizing effects demonstrated per DIN EN ISO 10993-5 and DIN EN ISO 10993-10
+2 more records
Product overview1 text field

JeNaCell offers a portfolio of biosynthetic cellulose products centered around their base material biocellic® and wound dressing brand epicite®. The product line includes three epicite® variants: epicite® BALANCE for chronic wounds, epicite® CALM for post-aesthetic treatment care, and epicite® RESCUE for burn treatment. The company also provides drug delivery systems and professional skin care applications using their 3D biosynthetic cellulose technology. Products are manufactured through a biotechnological fermentation process using bacteria to produce a nature-inspired hydropolymer with unique material properties.

Product and service4 records
1epicite® BALANCE
CategoryMedical wound dressings
Description

Wound dressings composed of biosynthetic cellulose and more than 95 percent isotonic saline, designed for the treatment of chronic and slow healing wounds.

2epicite® CALM
CategoryMedical aesthetics wound dressings
Description

World's first hydro-active wound dressing from biosynthetic cellulose in medical device quality, designed for post-treatment care in medical aesthetics following skin treatments such as peels, micro-needling, and laser treatments.

3epicite® RESCUE
CategoryMedical wound dressings
Description

Wound dressing tailored for advanced burn treatment that establishes an optimal moist wound environment, promotes effective wound healing, and provides a mild cooling effect and pain relief.

4biocellic®
CategoryBiosynthetic cellulose base material
Description

Soft, flexible, moist, and cool biosynthetic cellulose base material produced through biotechnological fermentation from sugar; can be produced as fleeces, films, or fiber suspensions and tailored to different applications in drug delivery, medical devices, and cosmetics.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US regenerative medicine company specializing in bioengineered skin substitutes and wound care products (Apligraf, Dermagraft). Comparable as a bioengineered-material specialist selling into the same advanced wound care end-market.

2Bowil Biotech
TypeDirect peer
Description

Polish producer of bacterial cellulose wound dressings (CelMat). Direct competitor in biosynthetic cellulose-based wound care, the most head-to-head comparable to JeNaCell's epicite® line in terms of material technology.

TypeBroad incumbent
Description

Publicly-listed wound care specialist (Aquacel, DuoDERM). Comparable as a chronic wound and post-surgical dressing competitor with similar hospital-channel go-to-market.

TypeBroad incumbent
Description

Danish wound and skin care specialist (Biatain, Comfeel). Direct competitor in advanced wound dressings with global presence and strong reimbursement relationships.

TypeBroad incumbent
Description

Diversified medical products business including advanced wound dressings (Tegaderm). Competes in same hospital channel and has far greater scale, distribution, and R&D resources.

TypeBroad incumbent
Description

Major advanced wound management player (Allevyn, PICO). Competes in the same chronic wound and burn dressing category that epicite® addresses, with established global distribution and clinical evidence base.

TypeDirect peer
Description

US-based regenerative medicine company selling dehydrated human amnion/chorion membrane allografts for wound care and surgical recovery. Comparable as a premium-priced bio-material wound-care specialist competing for similar clinical use cases.

TypeEmerging player
Description

Swedish medtech focused on advanced wound care, including burns and chronic wounds. Comparable emerging specialist competing in the same burn and chronic wound dressing category as epicite® RESCUE and BALANCE.

TypeBroad incumbent
Description

JeNaCell's parent company and the platform through which its products are commercialized. Evonik's broader Health Care division (including pharmaceutical excipients, drug delivery) provides adjacent peer context as the distribution and development backbone.

TypeBroad incumbent
Description

Global leader in advanced wound care (Mepilex, Mepitel) and single-use surgical products. Directly competes with epicite® in the hospital wound-dressing market with much broader portfolio, sales force, and reimbursement infrastructure.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

JeNaCell

Biomedical Materialsjenacell.com

JeNaCell GmbH is a German biosynthetic cellulose manufacturer producing epicite® wound dressings and biocellic® base materials for medical device, pharmaceutical, and cosmetic industry partners. A wholly-owned Evonik Industries subsidiary founded in 2012.

What JeNaCell does

JeNaCell GmbH is a German specialty biomaterials company that develops and manufactures biosynthetic cellulose products for medical device, pharmaceutical, and professional skin care applications. Founded in 2012 as a spin-off from Friedrich Schiller University of Jena and acquired by Evonik Industries AG in 2021, the company operates today as a wholly-owned subsidiary within Evonik's Health Care division, with its headquarters and production facilities in Jena, Germany.

The company's core technology is a proprietary biotechnological fermentation process that uses a protected acetic acid bacteria strain to produce biosynthetic cellulose — a nature-inspired hydropolymer consisting of approximately 5% cellulose and 95% water with a 3D nanofiber network. Manufacturing is conducted at commercial scale using a globally unique, automated technology enabling continuous planar production, and the production process is certified to DIN EN ISO 13485:2016. JeNaCell's product portfolio centers on two brands: the biocellic® base material, offered for custom development partnerships in drug delivery, transdermal patches, and dermatological formulations, and the epicite® wound dressing line, with three variants — epicite® BALANCE for chronic wounds, epicite® CALM for post-aesthetic treatment care, and epicite® RESCUE for advanced burn treatment.

The business operates an enterprise field-sales go-to-market, engaging medical device, pharmaceutical, and cosmetic customers through direct contact, trade show participation, and scientific congress presence across Europe and globally. Revenue is generated through three primary streams: branded epicite® product sales, custom development services leveraging JeNaCell's process and product design expertise, and licensing of biocellic® base material to industrial partners. Pricing is not publicly disclosed and is handled via direct inquiry. The company maintains a small team (1-10 employees) and provides no public revenue figures.

JeNaCell firmographics

Firmographics
Name
JeNaCell
Legal name
JeNaCell GmbH
Website
https://jenacell.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
JeNaCell GmbH is a German biosynthetic cellulose manufacturer producing epicite® wound dressings and biocellic® base materials for medical device, pharmaceutical, and cosmetic industry partners. A wholly-owned Evonik Industries subsidiary founded in 2012.
Ownership category
akta.pro rank

JeNaCell industry classification

Industry
Product category
Biomedical Materials
NAICS
Artificial and Synthetic Fibers and Filaments Manufacturing (32522), Medicinal and Botanical Manufacturing (325411)
SIC
Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) (2820), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYIMAMALAD
Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters)
SECONDARYIMAMALAB
Biochemicals & Bio-based Platform Chemicals (cellulose sugars, lignin derivatives, organic acids)
SECONDARYIMAMALAL
Biorefinery Technology & Contract Processing (fractionation, tolling, scale-up)
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Biosynthetic cellulose
  • Wound care dressings
  • Biotech biomaterials
  • Drug delivery systems
  • Medical device materials

Where JeNaCell is headquartered

Location

Headquarters

HQ city
Jena
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

JeNaCell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales (epicite® Brand): Sale of branded wound dressing products including epicite® BALANCE for chronic wounds, epicite® CALM for medical aesthetics post-treatment care, and epicite® RESCUE for advanced burn treatment. Products are medical device quality hydro-active dressings.
  2. Custom Development Services: Partnering with customers to develop customized biosynthetic cellulose solutions for drug delivery, medical devices, and cosmetic applications. Customers benefit from JeNaCell's expertise in process and product design, biosynthetic cellulose technology, and academic/industrial partner network.
  3. biocellic® Material Licensing: Licensing of biosynthetic cellulose base material biocellic® to pharmaceutical and cosmetic companies for custom developments in drug delivery systems, transdermal patches, and dermatological applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

JeNaCell product offering

Product offering

Core offering

JeNaCell develops and manufactures biosynthetic cellulose-based products using a proprietary biotechnological fermentation process with acetic acid bacteria. The portfolio centers on the biocellic® base material and the epicite® wound dressing brand (BALANCE for chronic wounds, CALM for post-aesthetic treatment care, RESCUE for advanced burn treatment), supported by custom biomaterial development services for medical device, pharmaceutical, and cosmetic industry partners.

Product overview

JeNaCell offers a portfolio of biosynthetic cellulose products centered around their base material biocellic® and wound dressing brand epicite®. The product line includes three epicite® variants: epicite® BALANCE for chronic wounds, epicite® CALM for post-aesthetic treatment care, and epicite® RESCUE for burn treatment. The company also provides drug delivery systems and professional skin care applications using their 3D biosynthetic cellulose technology. Products are manufactured through a biotechnological fermentation process using bacteria to produce a nature-inspired hydropolymer with unique material properties.

Differentiator

Problem solved

Functional benefit

Brands

  • epicite® BALANCE: Wound dressings designed for the treatment of chronic and slow healing wounds, composed of biosynthetic cellulose and more than 95 percent isotonic saline.
  • epicite® CALM
  • epicite® RESCUE
  • biocellic®

Products and services

  • epicite® BALANCE Wound dressings composed of biosynthetic cellulose and more than 95 percent isotonic saline, designed for the treatment of chronic and slow healing wounds.
  • epicite® CALM World's first hydro-active wound dressing from biosynthetic cellulose in medical device quality, designed for post-treatment care in medical aesthetics following skin treatments such as peels, micro-needling, and laser treatments.
  • epicite® RESCUE Wound dressing tailored for advanced burn treatment that establishes an optimal moist wound environment, promotes effective wound healing, and provides a mild cooling effect and pain relief.
  • biocellic® Soft, flexible, moist, and cool biosynthetic cellulose base material produced through biotechnological fermentation from sugar; can be produced as fleeces, films, or fiber suspensions and tailored to different applications in drug delivery, medical devices, and cosmetics.

Quantifiable outcome

  • No cytotoxic or sensitizing effects demonstrated per DIN EN ISO 10993-5 and DIN EN ISO 10993-10
  • +2 more outcomes

Companies that use JeNaCell

Customer profile

Segments3 records

Ideal customer profiles3 records

JeNaCell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

JeNaCell partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

JeNaCell competitors and assessment

Company assessment

Direct peers

  • Organogenesis: US regenerative medicine company specializing in bioengineered skin substitutes and wound care products (Apligraf, Dermagraft). Comparable as a bioengineered-material specialist selling into the same advanced wound care end-market.
  • Bowil Biotech: Polish producer of bacterial cellulose wound dressings (CelMat). Direct competitor in biosynthetic cellulose-based wound care, the most head-to-head comparable to JeNaCell's epicite® line in terms of material technology.
  • MiMedx: US-based regenerative medicine company selling dehydrated human amnion/chorion membrane allografts for wound care and surgical recovery. Comparable as a premium-priced bio-material wound-care specialist competing for similar clinical use cases.

Broad incumbents

  • ConvaTec: Publicly-listed wound care specialist (Aquacel, DuoDERM). Comparable as a chronic wound and post-surgical dressing competitor with similar hospital-channel go-to-market.
  • Coloplast: Danish wound and skin care specialist (Biatain, Comfeel). Direct competitor in advanced wound dressings with global presence and strong reimbursement relationships.
  • 3M Health Care (Medical Solutions): Diversified medical products business including advanced wound dressings (Tegaderm). Competes in same hospital channel and has far greater scale, distribution, and R&D resources.
  • Smith+Nephew: Major advanced wound management player (Allevyn, PICO). Competes in the same chronic wound and burn dressing category that epicite® addresses, with established global distribution and clinical evidence base.
  • Evonik Industries (Health Care division): JeNaCell's parent company and the platform through which its products are commercialized. Evonik's broader Health Care division (including pharmaceutical excipients, drug delivery) provides adjacent peer context as the distribution and development backbone.
  • Mölnlycke Health Care: Global leader in advanced wound care (Mepilex, Mepitel) and single-use surgical products. Directly competes with epicite® in the hospital wound-dressing market with much broader portfolio, sales force, and reimbursement infrastructure.

Emerging players

  • S2Medical AB: Swedish medtech focused on advanced wound care, including burns and chronic wounds. Comparable emerging specialist competing in the same burn and chronic wound dressing category as epicite® RESCUE and BALANCE.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

JeNaCell social profiles

Digital presence

JeNaCell compliance and trust

Trust signal

Compliance1 record

JeNaCell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

JeNaCell leadership team

Management profile

Number of profiles

Profiles2 records

JeNaCell funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

JeNaCell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JeNaCell

What does JeNaCell do?

JeNaCell develops and manufactures biosynthetic cellulose-based products using a proprietary biotechnological fermentation process with acetic acid bacteria. The portfolio centers on the biocellic® base material and the epicite® wound dressing brand (BALANCE for chronic wounds, CALM for post-aesthetic treatment care, RESCUE for advanced burn treatment), supported by custom biomaterial development services for medical device, pharmaceutical, and cosmetic industry partners.

Is JeNaCell a public or private company?

JeNaCell is a private company. It is classified as corporate owned and is currently operating.

When was JeNaCell founded?

JeNaCell was founded in 2012. It employs 11 to 50 people.

Where is JeNaCell based?

JeNaCell is headquartered in Jena, Germany, in the Europe region.

How does JeNaCell make money?

Three revenue lines are on record. Product Sales (epicite® Brand) is the primary driver. The others are custom Development Services and biocellic® Material Licensing.

Who are JeNaCell's main competitors?

Direct peers on record are Organogenesis, Bowil Biotech and MiMedx. Broad incumbents are ConvaTec, Coloplast, 3M Health Care (Medical Solutions), Smith+Nephew, Evonik Industries (Health Care division) and Mölnlycke Health Care. S2Medical AB is listed as an emerging player.

Does JeNaCell have an API?

No public API is recorded for JeNaCell.

What industry is JeNaCell in?

JeNaCell's product category is Biomedical Materials. Its primary akta.pro industry code is IMAMALAD, Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters), with a secondary code of IMAMALAB, Biochemicals & Bio-based Platform Chemicals (cellulose sugars, lignin derivatives, organic acids). Its NAICS code is 32522 and its SIC code is 2820.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mpo-magJeNaCell Releases Wound Dressing epicite balanceJeNaCell launched the epicite balance wound dressing for the German market, targeting chronic wounds with low to medium exudation. The biosynthetic cellulose dressing is distributed through Coopmed ApS to hospitals and homecare centers. It is the latest addition to JeNaCell's portfolio, which includes epicite hydro.HighHTGF Exit JeNaCellEvonik has fully acquired the German biotech company JeNaCell, enhancing its biomaterials portfolio aimed at medical technology. JeNaCell specializes in biotechnology-derived cellulose used for wound care and dermatology, and its integration into Evonik's operations will accelerate its health care business expansion. This acquisition reflects the growing cooperation between startups and corporations in the innovative landscape of Germany.Plastics TodayEvonik Acquires Biomaterials Company JeNaCellEvonik has acquired German biotech company JeNaCell, integrating its biotechnologically derived cellulose portfolio into its healthcare business. This move supports Evonik's strategic shift to increase system solutions in its Nutrition & Care division from 20% to over 50% by 2030. The acquisition allows JeNaCell to expand its customer base and application areas for technologies used in wound care and skincare.FinSMEsJeNaCell Raises Additional Financing - FinSMEsJeNaCell, a Jena-based biotech, raised a Series A financing of undisclosed amount. Backers include Evonik Industries, bm-t, and Sparkasse Jena, with funds for production capacity and distribution network expansion. The company develops nanocellulose for medicine and cosmetics.FinSMEsJeNaCell Raises €700K in Seed FundingJeNaCell GmbH, a Jena-based biomaterial maker, raised €700k in seed funding from High-Tech Gründerfonds and STIFT. The company will use the capital to optimize products, build an automated production facility, and prepare for market introduction. It is a spin-off of Friedrich Schiller University in Jena.